Advertisement

Search Results

Advertisement



Your search for Matthew Stenger,Matthew Stenger matches 6173 pages

Showing 1 - 50


breast cancer

WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS

As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal...

prostate cancer

GnRH Agonist Therapy for Prostate Cancer and Cardiovascular Disease Risk in Men With Type 2 Diabetes

In a Swedish population-based cohort study reported in JAMA Network Open, Lin et al found that men with type 2 diabetes receiving gonadotropin-releasing hormone (GnRH) agonists for prostate cancer were more likely to have an increased risk for developing cardiovascular disease compared with those...

breast cancer

Breast Induration Risk With Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Node-Negative Early Disease

As reported in the Journal of Clinical Oncology by Offersen et al, the phase III Danish Breast Cancer Group Partial Breast Irradiation Trial showed that partial-breast irradiation was noninferior to whole-breast irradiation in terms of the risk for breast induration in women aged ≥ 60 years...

breast cancer

Locoregional Recurrence With Predefined Risk-Based De-escalation of Radiotherapy After Primary Chemotherapy in cT1–2N1 Breast Cancer

As reported in The Lancet Oncology by de Wild et al, 5-year follow-up from a Dutch prospective registry study (RAPCHEM, BOOG 2010-03) showed low rates of locoregional recurrence with de-escalation of adjuvant radiotherapy according to predefined risk levels in women receiving primary chemotherapy...

gastrointestinal cancer

INTRIGUE Trial: Second-Line Ripretinib vs Sunitinib in Advanced GIST

As reported in the Journal of Clinical Oncology by Bauer et al, the phase III INTRIGUE trial showed no significant progression-free survival benefit with second-line ripretinib vs sunitinib in imatinib-pretreated patients with gastrointestinal stromal tumor (GIST), including among patients with KIT ...

issues in oncology

Does Daily Insulin Dose Affect Cancer Risk in Patients With Type 1 Diabetes?

In an analysis reported in JAMA Oncology, Zhong and Mao found that a higher daily insulin dose was associated with an increased risk of cancer diagnosis in patients with type 1 diabetes. Study Details The analysis used data from the Diabetes Control and Complications Trial (DCCT) and the...

issues in oncology
colorectal cancer

Models to Assess Impact of Centralization of Specialist Cancer Services in England

In a study reported in The Lancet Oncology, Aggarwal et al identified the impact of several models of centralization of specialist cancer services in England, using rectal cancer surgery as an example. As stated by the investigators, “Centralization of specialist cancer services is occurring in...

breast cancer

Time to Initiation of Adjuvant Endocrine Therapy and Likelihood of Adherence in Medicaid-Insured Women With Breast Cancer

In a population-based retrospective cohort study reported in JAMA Network Open, Sood et al found that longer time to adjuvant endocrine therapy initiation in Medicaid-insured women with breast cancer was associated with a reduced likelihood of short- and long-term adherence to treatment. As stated...

prostate cancer

PSA Screening and Prostate Cancer Mortality Among Black and White Veterans

In a study reported in JAMA Oncology, Sherer et al found that prostate-specific antigen (PSA) screening was associated with reduced prostate cancer mortality among both non-Hispanic Black and non-Hispanic White U.S. veterans who developed prostate cancer. Annual vs some screening was associated...

sarcoma

Evaluating Strategies for Treating Pediatric Metastatic Rhabdomyosarcoma

In a report in the Journal of Clinical Oncology, Schoot et al provided findings from the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 and pooled findings of MTS 2008 with those of the concurrent BERNIE study, both of which evaluated strategies for the treatment of pediatric...

issues in oncology

Characteristics of Data Supporting FDA Initial Approval and Subsequent Indications for New Cancer Drugs

In a study reported in the Journal of Clinical Oncology, Michaeli and Michaeli described data supporting U.S. Food and Drug Administration (FDA) initial approval and subsequent indications for new cancer drugs from 2003 through 2021. Study Details Clinical trial evidence supporting approval for...

skin cancer

Long-Term Regional Disease Control With Sentinel Lymph Node Biopsy in Patients With Melanoma

In an analysis of the Multicenter Selective Lymphadenectomy Trial II reported in JAMA Surgery, Crystal et al found that patients with melanoma with sentinel lymph node (SLN) metastasis who were randomly assigned to observation vs completion lymph node dissection (CLND) following SLN biopsy...

health-care policy

U.S. Cancer Care Facility Acceptance of Medicaid for Simulated Patients With Newly Diagnosed Common Cancers

In a study reported in JAMA Network Open, Marks et al found that only two-thirds of a sample of U.S. Commission on Cancer–accredited cancer care facilities accepted Medicaid insurance for the treatment of four common cancers in a simulated cohort of adult patients with newly diagnosed disease....

hepatobiliary cancer

Addition of Transarterial Chemoembolization to Lenvatinib in First-Line Treatment of Advanced Hepatocellular Carcinoma

An interim analysis of the Chinese phase III LAUNCH trial was reported in the Journal of Clinical Oncology by Peng et al. The researchers found that the addition of transarterial chemoembolization to lenvatinib improved overall survival in patients with advanced hepatocellular carcinoma who were...

gastrointestinal cancer

5-Year Outcomes With Laparoscopic vs Open Distal Gastrectomy in Locally Advanced Gastric Cancer

In the 5-year follow-up of the Korean KLASS-02 trial reported in JAMA Surgery, Son et al found similar 5-year overall survival and relapse-free survival among patients with R0 resection using laparoscopic vs open distal gastrectomy in patients with locally advanced gastric cancer. Late...

prostate cancer

Second Primary Cancer Risk After Primary Radiotherapy vs Surgery or Other Treatment in Veterans With Localized Prostate Cancer

In a retrospective cohort study reported in JAMA Network Open, Bagshaw et al found that the risk of a second primary cancer at more than 1 year from diagnosis was significantly greater among U.S. veterans with localized prostate cancer who received primary radiotherapy vs those who received surgery ...

skin cancer

COLUMBUS Trial 5-Year Update: Encorafenib/Binimetinib vs Vemurafenib or Encorafenib in Advanced BRAF V600–Mutant Melanoma

In a 5-year update of part 1 of the phase III COLUMBUS trial reported in the Journal of Clinical Oncology, Dummer et al found a continued benefit of encorafenib plus binimetinib vs vemurafenib in patients with advanced BRAF V600–mutant melanoma. The trial supported the June 2018 approval of...

breast cancer

Long-Term Outcomes With Adjuvant Goserelin and Tamoxifen in Premenopausal Estrogen Receptor–Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Johansson et al, 20-year follow-up of the Stockholm trial (STO-5) has shown long-term reduction in the risk of distant recurrence with 2 years of adjuvant endocrine therapy with goserelin and tamoxifen vs no endocrine therapy in premenopausal women ...

multiple myeloma

MRD-Adapted Study of Elotuzumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Without Transplantation Intent

In a phase II trial reported in JAMA Oncology, Derman et al found that a measurable residual disease (MRD)-adapted strategy with elotuzumab (Elo) plus carfilzomib, lenalidomide, and dexamethasone (KRd) was associated with high rates of stringent complete response and MRD-negative status in patients ...

gynecologic cancers

Talazoparib Plus Avelumab in Recurrent Mismatch Repair–Proficient Endometrial Cancer

In a phase II trial reported in JAMA Oncology, Konstantinopoulos et al found that the combination of talazoparib and avelumab was active in patients with recurrent mismatch repair–proficient endometrial cancer. Study Details In the U.S. multicenter study, 35 evaluable women with measurable disease, ...

head and neck cancer

Enzalutamide in Advanced Androgen Receptor–Positive Salivary Gland Cancer

In a phase II trial (Alliance A091404) reported in the Journal of Clinical Oncology, Ho et al found that enzalutamide showed some activity in advanced androgen receptor–positive salivary gland cancer but failed to meet the predefined criterion for a successful strategy.   Study Details     In the...

cns cancers

Outcomes With Postconsolidation Dinutuximab-Based Immunotherapy for Neuroblastoma

In an analysis reported in the Journal of Clinical Oncology, Desai et al described outcomes with postconsolidation dinutuximab-based immunotherapy for high-risk neuroblastoma in a cohort of patients from the Children’s Oncology Group ANBL0032 trial following cessation of randomized treatment. Study ...

skin cancer
immunotherapy

Lenvatinib Plus Pembrolizumab for Advanced Melanoma Progressing on PD-1/PD-L1 Inhibitor Therapy

In the phase II LEAP-004 trial reported in Journal of Clinical Oncology, Arance et al found that the combination of lenvatinib and pembrolizumab was active in patients with advanced melanoma with confirmed progression on PD-1/PD-L1 inhibitors as monotherapy or in combination with other agents. As...

colorectal cancer

Duration of Adjuvant Oxaliplatin With 6 Months of Fluoropyrimidine Treatment in High-Risk Stage II or III Colorectal Cancer

In a Korean phase III noninferiority trial (KCSG CO09-07) reported in the Journal of Clinical Oncology, Kim et al found noninferiority in disease-free survival and reduced risk of neuropathy for adjuvant therapy with 3 vs 6 months of oxaliplatin plus 6 months of fluoropyrimidine treatment in...

gynecologic cancers

Frequent Aspirin Use and Risk of Ovarian Cancer

In an individual-level meta-analysis reported in the Journal of Clinical Oncology, Hurwitz et al found that frequent aspirin use was associated with reduced risk of ovarian cancer, including high-grade serous ovarian cancer and among women with multiple risk factors. Study Details The analysis...

breast cancer

Oral Paclitaxel Plus P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer

In a Latin American phase III trial reported in the Journal of Clinical Oncology, Hope S. Rugo, MD, and colleagues found that oral paclitaxel with the P-glycoprotein pump inhibitor encequidar produced a higher response rate and trends toward better survival outcomes vs intravenous (IV) paclitaxel...

survivorship

Long-Term Risk of Hospitalization for Infection in Childhood Cancer Survivors

In a population-based study reported in the Journal of Clinical Oncology, Chehab et al found that survivors of childhood cancer were at significantly increased risk of infections resulting in hospitalization vs comparators without cancer. Study Details The study involved children and adolescents...

lymphoma

Brentuximab Vedotin Plus AVD vs ABVD for the First-Line Treatment of Early-Stage Unfavorable-Risk Hodgkin Lymphoma

In a European phase II trial (BREACH) reported in the Journal of Clinical Oncology, Fornecker et al found that brentuximab vedotin (BV) plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) improved the rate of positron-emission tomography (PET)-negative status after two cycles of treatment vs...

solid tumors

Proton Craniospinal Irradiation vs Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis

In an interim analysis of a single-institution phase II trial reported in the Journal of Clinical Oncology, Yang et al found that proton craniospinal irradiation (pCSI) improved central nervous system (CNS) progression-free survival vs standard-of-care photon involved-field radiotherapy (IFRT) in...

lymphoma

Consolidation Radiotherapy vs Autologous Stem Cell Transplantation for Primary CNS Lymphoma

As reported in the Journal of Clinical Oncology by Houillier et al, 8-year follow-up in the French phase II PRECIS trial has shown a maintained event-free survival benefit with autologous stem cell transplantation (ASCT) vs whole-brain radiotherapy (WBRT) as consolidation in patients aged ≤ 60...

skin cancer

Risk Stratification and Treatment Implications for Patients With Early-Stage Melanoma and Sentinel Node Metastasis

In a study reported in the Journal of Clinical Oncology, Moncrieff et al found that patients with stage IIIA melanoma (per American Joint Committee on Cancer [AJCC], 8th edition) with sentinel node metastatic tumor deposits ≥ 0.3 mm are at higher risk of disease progression vs those with smaller...

leukemia
lymphoma

Zandelisib in Continuous or Intermittent Dosing Schedules With or Without Rituximab for Relapsed or Refractory B-Cell Malignancies

In a first-in-patients phase Ib study reported in The Lancet Oncology, John M. Pagel, MD, PhD, and colleagues identified the safety profiles of the PI3Kδ inhibitor zandelisib given in intermittent vs continuous dosing schedules with or without rituximab in patients with relapsed of refractory...

gynecologic cancers

Intensive vs Minimalist Follow-up Strategies for Patients in Remission After Surgery for Endometrial Cancer

In an Italian/French trial (TOTEM) reported in the Journal of Clinical Oncology, Zola et al found no difference in 5-year overall survival with intensive vs minimalist follow-up regimens in patients in complete clinical remission after surgery for endometrial cancer. Study Details In the...

pancreatic cancer

Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer: Overall Survival Analysis of the POLO Trial

As reported in the Journal of Clinical Oncology by Hedy L. Kindler, MD, FASCO, and colleagues, the final overall survival analysis of the phase III POLO trial showed no significant difference between the maintenance olaparib group vs the placebo group in patients with germline BRCA-mutated...

pancreatic cancer

Neoadjuvant mFOLFIRINOX With or Without Radiotherapy for Borderline Resectable Pancreatic Cancer

As reported in JAMA Oncology by Matthew H.G. Katz, MD, and colleagues, the National Clinical Trials Network phase II A021501 trial has shown better survival outcomes with neoadjuvant modified FOLFIRINOX (mFOLFIRINOX; oxaliplatin, irinotecan, leucovorin, fluorouracil) vs mFOLFIRINOX plus...

breast cancer
immunotherapy

KEYNOTE-355: Overall Survival With the Addition of Pembrolizumab to Chemotherapy in Advanced Triple-Negative Breast Cancer

As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III KEYNOTE-355 trial has shown improved overall survival with the addition of pembrolizumab to chemotherapy in previously untreated patients with advanced triple-negative breast cancer with a...

skin cancer

Diagnosing Basal Cell Carcinoma: Optical Coherence Tomography vs Punch Biopsy

In a Dutch trial reported in The Lancet Oncology, Adan et al found that optical coherence tomography (OCT)-guided diagnosis and treatment of basal cell carcinoma was noninferior to that with punch biopsy, currently the guideline-recommended standard for diagnosis and treatment. Study Details In the ...

gynecologic cancers

Effectiveness and Risk of Preterm Birth With Local Treatments for Cervical Malignancies

In a systematic review and network meta-analyses reported in The Lancet Oncology, Athanasiou et al described the comparative effectiveness of and risk of preterm birth with local excisional and ablative treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer. Study Details...

leukemia

Venetoclax Plus Gilteritinib in FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia

In a phase Ib study reported in the Journal of Clinical Oncology, Naval Daver, MD, and colleagues found that the doublet of venetoclax plus gilteritinib produced a high modified composite complete response rate in patients with FLT3-mutated relapsed or refractory acute myeloid leukemia. Dose...

supportive care
pancreatic cancer

Adherence to VTE Prophylaxis Guidelines After Pancreatic Cancer Surgery

In a U.S. retrospective cohort study reported in JAMA Surgery, Perry et al found that a very small percentage of patients filled prescriptions for guideline-recommended venous thromboembolism (VTE) prophylaxis after undergoing surgery for pancreatic cancer. As stated by the investigators, “VTE is...

pancreatic cancer
immunotherapy

Noncytotoxic Maintenance With Niraparib Plus Either Nivolumab or Ipilimumab in Platinum-Sensitive Advanced Pancreatic Cancer

In a single-institution phase Ib/II trial reported in The Lancet Oncology, Kim A. Reiss, MD, and colleagues found that maintenance treatment with niraparib/ipilimumab produced better 6-month progression-free survival rates than niraparib/nivolumab in patients with advanced pancreatic cancer without ...

cns cancers

COG Trial of Intensive Multimodality Therapy for Extraocular Retinoblastoma

As reported in the Journal of Clinical Oncology by Dunkel et al, the Children’s Oncology Group (COG) ARET0321 trial has shown high 1-year event-free survival rates with intensive multimodality therapy in patients with stage II, III, and IVa extraocular retinoblastoma. Study Details In the...

issues in oncology

Children With In Utero Exposure to Maternal Cancer: Short- and Long-Term Outcomes

In a Danish nationwide cohort study reported in the Journal of Clinical Oncology, Greiber et al found no apparent increased risk of mortality, overall somatic disease, or overall psychiatric disease among children exposed in utero to maternal cancer compared with to children without such exposure....

breast cancer

Time-Restricted Eating Intervention Reduces Cardiovascular Risk in Older Breast Cancer Survivors

In a Canadian single-institution feasibility study reported in JACC: CardioOncology, Amy A. Kirkham, PhD, of the University of Toronto, and colleagues found that a time-restricted eating intervention reduced cardiovascular risk among older breast cancer survivors with risk factors for...

breast cancer

Addition of Ribociclib to Letrozole Improves Survival in Women With HR-Positive, HER2-Negative Advanced Breast Cancer

As reported in The New England Journal of Medicine by Gabriel N. Hortobagyi, MD, of the Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, and colleagues, the protocol-specified final overall survival analysis of the phase III MONALEESA-2 trial has shown a significant...

leukemia
myelodysplastic syndromes

Eprenetapopt/Azacitidine Maintenance After Allogeneic HSCT for TP53-Mutant AML and MDS

In a phase II trial reported in the Journal of Clinical Oncology, Mishra et al found that maintenance treatment with the first-in-class small-molecule p53 reactivator eprenetapopt plus azacitidine following allogeneic hematopoietic stem cell transplantation (HSCT) was associated with “encouraging”...

sarcoma

Addition of Trabectedin to Doxorubicin in the First-Line Treatment of Advanced Leiomyosarcoma

In the French phase III LMS-04 trial reported in The Lancet Oncology, Pautier et al found that the addition of trabectedin to doxorubicin significantly prolonged progression-free survival as first-line treatment for patients with unresectable or metastatic leiomyosarcoma. Study Details In the...

lung cancer

Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC

As reported in The New England Journal of Medicine by Pasi A. Jänne, MD, PhD, and colleagues, findings in a phase II cohort of the multicohort KRYSTAL-1 phase I/II study indicate that the KRAS G12C inhibitor adagrasib showed activity in previously treated patients with unresectable or metastatic...

leukemia
lymphoma

Zanubrutinib vs Bendamustine/Rituximab in Previously Untreated Patients With CLL or SLL

As reported in The Lancet Oncology by Constantine S. Tam, MBBS, PhD, and colleagues, an interim analysis in the phase III SEQUOIA trial has shown significantly improved progression-free survival with first-line zanubrutinib vs bendamustine/rituximab in patients with chronic lymphocytic leukemia...

lymphoma
immunotherapy

Second-Line Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma Not Intended for HSCT

As reported in The Lancet Oncology by Sehgal et al, the phase II PILOT trial showed that the autologous, CD19-directed chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel produced a high response rate in the second-line treatment of patients with relapsed or refractory large...

Advertisement

Advertisement



Advertisement